Humanized antibodies that recognize beta amyloid peptide

• US 7,625,560 B2
• Filed: 12/15/2005
• Issued: 12/01/2009
• Est. Priority Date: 12/15/2004
• Status: Active Grant

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson), Wyeth LLC (Pfizer Inc.)
• Original Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson)
• Inventors: Basi, Guriq, Jacobsen, Jack Steven
• Primary Examiner(s): Haddad; Maher M
• Application Number:
  US11/304,986
• Publication Number:
  US 20060165682A1
• Time in Patent Office: 1,447 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/30 characterized by aspects of specificity or valency
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Claims

1. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the humanized immunoglobulin comprising;

(i) a light chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain; and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO;

4, and variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue in the light or heavy chain is substituted with the corresponding amino acid residue from the mouse 15C11 light or heavy chain variable region sequence, wherein the framework residue is selected from the group consisting of;

(a) a residue that non-covalently binds antigen directly;

(b) a residue adjacent to a CDR;

(c) a CDR-interacting residue; and

(d) a residue participating in the VL-VH interface.

11. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁷ M<sup>−

1</sup>.

12. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁸ M<sup>−

1</sup>.

13. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which specifically binds to beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁹ M<sup>−

1</sup>.

14. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, wherein the heavy chain isotype is γ

1.

15. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, wherein the heavy chain isotype is γ

4.

16. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which binds to soluble beta amyloid peptide (Aγ

).

17. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which binds to oligomeric beta amyloid peptide (Aβ

).

18. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which captures beta amyloid peptide (Aβ

).

19. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which crosses the blood-brain barrier in a patient.

20. The humanized immunoglobulin or antigen binding fragment of any one of claims 1, 2, 3, 4, 9, and 10, which reduces beta amyloid peptide (Aβ

) plaque burden in a patient.

22. A pharmaceutical composition comprising the humanized immunoglobulin of any one of claims 1, 2, 3 and 4 and a pharmaceutical carrier.

2. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the humanized immunoglobulin comprising;

(i) a light chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain; and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO;

4, and a variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue in both the light and heavy chain is substituted with the corresponding amino acid residue from the mouse 15C11 light or heavy chain variable region sequence, wherein the framework residue is selected from the group consisting of;

(a) a residue that non-covalently binds antigen directly;

(b) a residue adjacent to a CDR;

(c) a CDR-interacting residue; and

(d) a residue participating in the VL-VH interface.

3. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the humanized immunoglobulin comprising;

(i) a light chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain, and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO;

4, and a variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue in the light or heavy chain is substituted with the corresponding amino acid residue from the mouse 15C11 light chain or heavy variable region sequence, wherein the framework residue is a residue capable of affecting the light or heavy chain variable region conformation or function as identified by analysis of a three-dimensional model of the variable region.

5. The humanized immunoglobulin or antigen-binding fragment of claim 3 or 4, wherein the framework residue in the light chain is selected from the group consisting of a residue capable of interacting with antigen, a residue proximal to the antigen binding site, a residue capable of interacting with a CDR, a residue adjacent to a CDR, a residue within 6 Å

of a CDR residue, a canonical residue, a vernier zone residue, an interchain packing residue, a rare residue, and a glycoslyation site residue on the surface of the three-dimensional model.

6. The humanized immunoglobulin or antigen-binding fragment of claim 3 or 4, wherein the framework residue in the heavy chain is selected from the group consisting of a residue capable of interacting with antigen, a residue proximal to the antigen binding site, a residue capable of interacting with a CDR, a residue adjacent to a CDR, a residue within 6 Å

of a CDR residue, a canonical residue, a vernier zone residue, an interchain packing residue, a rare residue, and a glycoslyation site residue on the surface of the three-dimensional model.

7. The humanized immunoglobulin or antigen-binding fragment of claim 3 or 4, wherein the framework residue in the light chain is substituted at a position selected from the group consisting of position 2, 4, 35, 64, and 71 of the light chain as numbered according to Kabat.

8. The humanized immunoglobulin or antigen-binding fragment of claim 3 or 4, wherein the framework residue in the heavy chain is substituted at a position selected from the group consisting of position 26-30, 71, 93, 94, and 103 of the heavy chain as numbered according to Kabat.

4. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the humanized immunoglobulin comprising;

(i) a light chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain, and

(ii) a heavy chain comprising three complementarity determining regions (CDRs) from the 15C11 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO;

4, and a variable framework region from a human acceptor immunoglobulin heavy chain, provided that at least one framework residue in the light and heavy chain is substituted with the corresponding amino acid residue from the mouse 15C11 light or heavy chain variable region sequence, wherein the framework residue is a residue capable of affecting heavy chain variable region conformation or function as identified by analysis of a three-dimensional model of the variable region.

9. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the human immunoglobulin comprising;

(a) a light chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3) from the monoclonal antibody 15C11 light chain variable region sequence set forth as SEQ ID NO;

2, and a variable framework region from a human acceptor immunoglobulin light chain provided that at least one framework residue in the light chain is substituted with the corresponding amino acid residue from the 15C11 light chain variable region sequence, wherein the framework residue is selected from the group consisting of a canonical residue, a vernier residue, a packing residue and a rare residue; and

(b) a heavy chain comprising three complementarity determining regions (CDR1, CDR2 and CDR3) from the monoclonal antibody 15C11 immunoglobulin heavy chain variable region sequence set forth as SEQ ID NO;

4, and a variable framework region from a human acceptor immunoglobulin heavy chain provided that at least one framework residue in the heavy chain is substituted with the corresponding amino acid residue from the 15C11 heavy chain variable region sequence, wherein the framework residue is selected from a second group consisting of a canonical residue, a vernier residue, a packing residue and a rare residue.

10. A humanized immunoglobulin which specifically binds beta amyloid peptide (Aβ

), or antigen-binding fragment thereof, the human immunoglobulin comprising a light chain and a heavy chain, the light chain comprising the complementarity determining regions (CDR1, CDR2 and CDR3) of the 15C11 light chain variable region sequence set forth as SEQ ID NO;

2, and the heavy chain comprising the complementarity determining regions (CDR1, CDR2, and CDR3) of the 15C11 heavy chain variable region sequence set forth as SEQ ID NO;

4.

21. A chimeric immunoglobulin, which specifically binds beta amyloid peptide (Aβ

) with a binding affinity of at least 10⁷M<sup>−

1,</sup> comprising the light chain variable region sequence as set forth in amino acid residues 1-111 of SEQ ID NO;

2 and the heavy chain variable region sequence set forth in amino acid residues 1-112 of SEQ ID NO;

4, and comprising constant region sequences from a human immunoglobulin.